Drug Trial Radar · NCT07073820
A Study to Learn About the Study Medicine (Called PF-07868489) in People With Pulmonary Arterial Hypertension Who Have Previously Participated in a Clinical Study With PF-07868489
Last checked: Nov 20, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
42
Actual
Start
Nov 10, 2025
Primary completion
Oct 9, 2026
Study completion Oct 9, 2026
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Jul 18, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to learn about the long-term safety, tolerability and effects of the study medicine (PF-07868489) for the possible treatment of PAH. PAH is a condition in which there is high blood pressure in the arteries that carry blood from the heart to the lungs. This high pressure makes it harder for the heart to pump blood through those lungs, potentially damaging the right side of the heart. This is an open-label study. Which means that both the healthcare providers and the study participants are aware of the medicine being given. This study is also an extension study with study medicine (PF-07868489). An extension study allows patients from an earlier clinical study (also called as qualifying study) to continue participating to assess long-term benefits and safety of the medicine.
Conditions
- Pulmonary Hypertension
Interventions
PF-07868489Drug
Participants will receive subcutaneous doses of PF-07868489 every 4 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: Baseline up to week 111
- Number of Participants With Change From Baseline in Laboratory Tests ResultsTime frame: Baseline up to week 111
- Number of Participants With Vital Sign AbnormalitiesTime frame: Baseline up to week 111
Locations
27 sites in 10 countries. Site status is shown where the registry gives one.
UCSF Health St. Mary's Hospital
San Francisco, California
Heart and Vascular Center
San Francisco, California
UCSF Helen Diller Medical Center at Parnassus Heights
San Francisco, California
Mount Sinai Hospital
New York, New York
Royal Prince Alfred Hospital
Camperdown, New South Wales, Australia
Pulmonary Hypertension Research Queensland Pty Ltd
Auchenflower, Queensland, Australia
HUB Hôpital Erasme
Brussels, Belgium
UZ Leuven
Leuven, Belgium
Guangdong Provincial People's Hospital
Guangzhou, Guangdong, China
The Second Xiangya Hospital of Central South University
Changsha, Hunan, China
Zhongda Hospital Southeast University
Nanjing, Jiangsu, China
Shanghai Pulmonary Hospital
Shanghai, Shanghai Municipality, China
Vseobecna fakultni nemocnice v Praze
Prague, Czechia
Thoraxklinik-Heidelberg gGmbH
Heidelberg, Baden-Wurttemberg, Germany
Universitätsklinikum Regensburg
Regensburg, Bavaria, Germany
Universitaetsklinikum Giessen und Marburg GmbH
Giessen, Hesse, Germany
Universitätsmedizin Greifswald
Greifswald, Mecklenburg-Vorpommern, Germany
Universitaetsklinikum Carl Gustav Carus, Technischen Universitaet Dresden
Dresden, Saxony, Germany
National Hospital Organization Okayama Medical Center
Okayama, Japan
Kobe University Hospital
Kobe, Hyōgo, Japan
St. Marianna University Hospital
Kawasaki, Kanagawa, Japan
Gachon University Gil Medical Center
Incheon, Incheon-gwangyeoksi [incheon], South Korea
Seoul National University Hospital
Seoul, Seoul-teukbyeolsi [seoul], South Korea
Severance Hospital, Yonsei University Health System
Seoul, Seoul-teukbyeolsi [seoul], South Korea
Samsung Medical Center
Seoul, Seoul-teukbyeolsi [seoul], South Korea
Hospital Universitario 12 de Octubre
Madrid, Spain
Hammersmith Hospital
London, Greater London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.